Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Klawitter, Jelena ^a,b   Zafar, Iram ^b   Klawitter, Jost ^a   Pennington, Alexander T ^a   Klepacki, Jacek ^a   Gitomer, Berenice Y ^b   Schrier, Robert W ^b   Christians, Uwe ^a   Edelstein, Charles L ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Biomarkers; Endothelial dysfunction; Inflammation; Lovastatin; PKD Han:SPRD rat model

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 13 HYDROXYOCTADECADIENOIC ACID; ALCOHOL; ALLANTOIN; ARGININE; BIOLOGICAL MARKER; FATTY ACID; HOMOCYSTEINE; LACTIC ACID; LEUKOTRIENE B4; LIPID; LONG CHAIN FATTY ACID; MEVINOLIN; NITRIC OXIDE; PERCHLORIC ACID; TISSUE EXTRACT; UNCLASSIFIED DRUG; WATER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CITRIC ACID CYCLE; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; ENERGY; ENERGY METABOLISM; EXTRACTION; FATTY ACID METABOLISM; FEMALE; GLYCOLYSIS; INFLAMMATION; KIDNEY CELL; KIDNEY PARENCHYMA; KIDNEY POLYCYSTIC DISEASE; LIPID ANALYSIS; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; RAT STRAIN; TANDEM MASS SPECTROMETRY; ANIMAL; DISEASE MODEL; MALE; METABOLISM; POLYCYSTIC KIDNEY DISEASES; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; LOVASTATIN; MALE; POLYCYSTIC KIDNEY DISEASES; RATS; TREATMENT OUTCOME;

EID: 84880929156     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-165     Document Type: Article

References (50)

1. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. Schrier RW, J Am Soc Nephrol 2009 20 9 1888 1893 10.1681/ASN.2008080882 19696226
2. Pathophysiology of adult polycystic kidney disease. Gabow PA, Schrier RW, Adv Nephrol Necker Hosp 1989 18 19 32 2493716
3. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK, Science 1999 285 5431 1276 1279 10.1126/science.285.5431.1276 10455056 (Pubitemid 29398616)
4. Resolution of inflammation: the beginning programs the end. Serhan CN, Savill J, Nat Immunol 2005 6 12 1191 1197 10.1038/ni1276 16369558 (Pubitemid 43045627)
5. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Bianchi S, Bigazzi R, Caiazza A, Campese VM, Am J Kidney Dis 2003 41 3 565 570 10.1053/ajkd.2003.50140 12612979 (Pubitemid 36278373)
6. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. van Dijk MA, Kamper AM, van Veen S, Souverijn JH, Blauw GJ, Nephrol Dial Transplant 2001 16 11 2152 2157 10.1093/ndt/16.11.2152 11682660 (Pubitemid 33062136)
7. Lovastatin has direct renal hemodynamic effects in a rodent model. Stowe NT, Inman SR, Tapolyai M, Brouhard BH, Hodge EE, Novick AC, J Urol 1996 156 1 249 252 10.1016/S0022-5347(01)66010-5 8648816 (Pubitemid 26185692)
8. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Imig JD, Am J Physiol Renal Physiol 2005 289 3 496 F503 10.1152/ajprenal.00350.2004 16093425 (Pubitemid 41208461)
9. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Park JK, Muller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F, Bieringer M, Schafer O, Lindschau C, Schneider W, et al. Kidney Int 2000 58 4 1420 1430 10.1046/j.1523-1755.2000. 00304.x 11012877
10. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC, J Am Soc Nephrol 2003 14 6 1605 1613 10.1097/01.ASN.0000068461.45784.2F 12761262 (Pubitemid 36687063)
11. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, et al. Circulation 2005 112 2 171 178 10.1161/CIRCULATIONAHA.104.517565 15998677 (Pubitemid 40982298)
12. Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Gile RD, Cowley BD Jr, Gattone VH 2nd, O'Donnell MP, Swan SK, Grantham JJ, Am J Kidney Dis 1995 26 3 501 507 10.1016/0272-6386(95)90497-2 7645559
13. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Zafar I, Tao Y, Falk S, McFann K, Schrier RW, Edelstein CL, Am J Physiol Renal Physiol 2007 293 3 854 F859 10.1152/ajprenal.00059.2007 17581927 (Pubitemid 47403356)
14. Autosomal-dominant polycystic kidney disease in the rat. Cowley BD Jr, Gudapaty S, Kraybill AL, Barash BD, Harding MA, Calvet JP, Gattone VH 2nd, Kidney Int 1993 43 3 522 534 10.1038/ki.1993.79 8455352 (Pubitemid 23071934)
15. Relative roles of nitric oxide and cyclo-oxygenase and lipoxygenase products of arachidonic acid in the contractile responses of rat renal arcuate arteries. Wu XC, Richards NT, Michael J, Johns E, Br J Pharmacol 1994 112 2 369 376 10.1111/j.1476-5381.1994.tb13081.x 8075854
16. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Harris KP, Purkerson ML, Yates J, Klahr S, Am J Kidney Dis 1990 15 1 16 23 2294729 (Pubitemid 20086576)
17. Simultaneous lipidomic analysis of three families of bioactive lipid mediators leukotrienes, resolvins, protectins and related hydroxy-fatty acids by liquid chromatography/electrospray ionisation tandem mass spectrometry. Masoodi M, Mir AA, Petasis NA, Serhan CN, Nicolaou A, Rapid Commun Mass Spectrom 2008 22 2 75 83 10.1002/rcm.3331 18059001 (Pubitemid 351156118)
18. Bezielle (BZL101)-induced oxidative stress damage followed by redistribution of metabolic fluxes in breast cancer cells: a combined proteomic and metabolomic study. Klawitter J, Gurshtein J, Corby K, Fong S, Tagliaferri M, Quattrochi L, Cohen I, Shtivelman E, Christians U, Int J Cancer 2011 129 12 2945 2957 10.1002/ijc.25965 21509784
19. Cytokine profile in autosomal dominant polycystic kidney disease. Merta M, Tesar V, Zima T, Jirsa M, Rysava R, Zabka J, Biochem Mol Biol Int 1997 41 3 619 624 9090470 (Pubitemid 27154142)
20. Effects of specific genes activating RAGE on polycystic kidney disease. Park EY, Seo MJ, Park JH, Am J Nephrol 2010 32 2 169 178 10.1159/000315859 20606421
21. Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension. Sarkis A, Lopez B, Roman RJ, Curr Opin Nephrol Hypertens 2004 13 2 205 214 10.1097/00041552-200403000-00009 15202615 (Pubitemid 38373143)
22. Autosomal-dominant polycystic kidney disease in infancy and childhood: progression and outcome. Shamshirsaz AA, Reza Bekheirnia M, Kamgar M, Johnson AM, McFann K, Cadnapaphornchai M, Nobakhthaghighi N, Schrier RW, Kidney Int 2005 68 5 2218 2224 10.1111/j.1523-1755.2005.00678.x 16221221 (Pubitemid 43117796)
23. Progression of autosomal-dominant polycystic kidney disease in children. Fick-Brosnahan GM, Tran ZV, Johnson AM, Strain JD, Gabow PA, Kidney Int 2001 59 5 1654 1662 10.1046/j.1523-1755.2001.0590051654.x 11318935 (Pubitemid 32366566)
24. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, et al. Circulation 2009 119 19 2545 2552 10.1161/CIRCULATIONAHA.108.844506 19414634
25. Elevated augmentation index derived from peripheral arterial tonometry is associated with abnormal ventricular-vascular coupling. Heffernan KS, Patvardhan EA, Hession M, Ruan J, Karas RH, Kuvin JT, Clin Physiol Funct Imaging 2010 30 5 313 317 20545714
26. Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease. Heffernan KS, Kuvin JT, Sarnak MJ, Perrone RD, Miskulin DC, Rudym D, Chandra P, Karas RH, Menon V, Nephrol Dial Transplant 2011 26 8 2515 2521 10.1093/ndt/gfq806 21292815
27. Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease. Menon V, Rudym D, Chandra P, Miskulin D, Perrone R, Sarnak M, Clin J Am Soc Nephrol 2010 6 1 7 13 20829421
28. Products of 12/15-lipoxygenase upregulate the angiotensin II receptor. Xu ZG, Yuan H, Lanting L, Li SL, Wang M, Shanmugam N, Kato M, Adler SG, Reddy MA, Natarajan R, J Am Soc Nephrol 2008 19 3 559 569 10.1681/ASN.2007080939 18235084 (Pubitemid 351355399)
29. Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells. Reddy MA, Adler SG, Kim YS, Lanting L, Rossi J, Kang SW, Nadler JL, Shahed A, Natarajan R, Am J Physiol Renal Physiol 2002 283 5 985 F994 12372774
30. Physiologic and pathophysiologic roles of lipid mediators in the kidney. Hao CM, Breyer MD, Kidney Int 2007 71 11 1105 1115 10.1038/sj.ki.5002192 17361113 (Pubitemid 46809137)
31. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, et al. N Engl J Med 2008 359 6 584 592 10.1056/NEJMoa0706130 18687639
32. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, et al. JAMA: j Am Med Assoc 2011 305 23 2432 2439 10.1001/jama.2011.826
33. Circulating alphaKlotho influences phosphate handling by controlling FGF23 production. Smith RC, O'Bryan LM, Farrow EG, Summers LJ, Clinkenbeard EL, Roberts JL, Cass TA, Saha J, Broderick C, Ma YL, et al. J Clin Invest 2012 122 12 4710 4715 10.1172/JCI64986 23187128
34. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M, Investigators H, J Am Soc Nephrol 2011 22 10 1913 1922 10.1681/ASN.2010121224 21903574
35. FGF23 induces left ventricular hypertrophy. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, et al. J Clin Invest 2011 121 11 4393 4408 10.1172/JCI46122 21985788
36. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Pavik I, Jaeger P, Kistler AD, Poster D, Krauer F, Cavelti-Weder C, Rentsch KM, Wuthrich RP, Serra AL, Kidney Int 2011 79 2 234 240 10.1038/ki.2010.375 20944552
37. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Brunner HR, Am J Cardiol 2001 87 8A 3C 9C 11334762 (Pubitemid 32385756)
38. Role of superoxide in angiotensin II-induced but not catecholamine- induced hypertension. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG, Circulation 1997 95 3 588 593 10.1161/01.CIR.95.3.588 9024144 (Pubitemid 27063033)
39. Angiotensin II and the endothelium: diverse signals and effects. Watanabe T, Barker TA, Berk BC, Hypertension 2005 45 2 163 169 10.1161/01.HYP. 0000153321.13792.b9 15630047 (Pubitemid 40179951)
40. Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. Wang D, Iversen J, Strandgaard S, J Am Soc Nephrol 2000 11 8 1371 1376 10906150 (Pubitemid 30483453)
41. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Wang D, Iversen J, Wilcox CS, Strandgaard S, Kidney Int 2003 64 4 1381 1388 10.1046/j.1523-1755.2003.00236.x 12969157 (Pubitemid 37153804)
42. Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. Wang D, Strandgaard S, Borresen ML, Luo Z, Connors SG, Yan Q, Wilcox CS, Am J Kidney Dis 2008 51 2 184 191 10.1053/j.ajkd.2007.09.020 18215696
43. Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension. Wang D, Strandgaard S, Iversen J, Wilcox CS, Am J Physiol Regul Integr Comp Physiol 2009 296 2 195 R200 18685064
44. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E, Fliser D, J Am Soc Nephrol 2002 13 1 170 176 11752034 (Pubitemid 34042024)
45. Hyperhomocysteinemia: an independent risk factor for vascular disease. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I, N Engl J Med 1991 324 17 1149 1155 10.1056/NEJM199104253241701 2011158
46. Enzymatic methyl esterification of erythrocyte membrane proteins is impaired in chronic renal failure. Evidence for high levels of the natural inhibitor S-adenosylhomocysteine. Perna AF, Ingrosso D, Zappia V, Galletti P, Capasso G, De Santo NG, J Clin Invest 1993 91 6 2497 2503 10.1172/JCI116485 8514862 (Pubitemid 23182501)
47. Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients. Valli A, Carrero JJ, Qureshi AR, Garibotto G, Barany P, Axelsson J, Lindholm B, Stenvinkel P, Anderstam B, Suliman ME, Clin Chim Acta 2008 395 1-2 106 110 18565329
48. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS, Kidney Int 2000 58 1 353 362 10.1046/j.1523-1755.2000.00173.x 10886582 (Pubitemid 30429882)
49. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. Stenvinkel P, Pecoits-Filho R, Lindholm B, J Am Soc Nephrol 2003 14 7 1927 1939 10.1097/01.ASN.0000069165.79509.42 12819254 (Pubitemid 36750489)
50. Effect of dialysis dose and membrane flux in maintenance hemodialysis. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, et al. N Engl J Med 2002 347 25 2010 2019 10.1056/NEJMoa021583 12490682 (Pubitemid 35461657)